title: FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
abstract: BACKGROUND
  Early prediction of response to therapy may offer the potential to identify patients who will benefit from standard conventional therapy. The objective of this study was to determine the predictive value of FDG-PET as an early response indicator after 1 cycle of chemotherapy for progression-free survival (PFS) in diffuse large cell lymphoma (DLCL) and classic Hodgkin disease (HD).
  
  
  METHODS
  FDG-PET was performed before, after 1 cycle, and after completion of chemotherapy in 47 patients. The patients were followed with a median follow-up of 21 months (range, 3-47 months). PFS was compared between PET-positive and PET-negative patients after 1 cycle and after completion of therapy.
  
  
  RESULTS
  All PET-negative patients after 1 cycle (n = 31) had sustained complete remission with a median follow-up of 28 months. Fourteen of 16 PET-positive patients after 1 cycle had refractory disease or relapsed (median PFS, 5.5 months). There were 2 false-positive results, 1 with an active infection at the biopsy site and the other in a patient who had been in remission after radiation therapy. There was good agreement between the results obtained after 1 cycle and at completion of therapy (kappa, 0.80); however, the negative predictive value was higher for FDG-PET after 1 cycle than after completion of chemotherapy (100% vs 91.4%), although not statistically different (P = .40).
  
  
  CONCLUSIONS
  FDG-PET had a high prognostic value after 1 cycle of chemotherapy, thus it can be a valid alternative for posttreatment evaluation of DLCL and HD and may offer the potential for change in treatment paradigms.
authors.affiliation: Department of Radiology, Division of Nuclear Medicine, Mount Sinai School of Medicine, New York, New York, USA. late.kostakoglu@msnyuhealth.org
authors.forename: Lale
authors.initials: L
authors.lastname: Kostakoglu
authors.forename: Stanley J
authors.initials: SJ
authors.lastname: Goldsmith
authors.forename: John P
authors.initials: JP
authors.lastname: Leonard
authors.forename: Paul
authors.initials: P
authors.lastname: Christos
authors.forename: Richard R
authors.initials: RR
authors.lastname: Furman
authors.forename: Tamer
authors.initials: T
authors.lastname: Atasever
authors.forename: Angely
authors.initials: A
authors.lastname: Chandramouly
authors.forename: Sumeet
authors.initials: S
authors.lastname: Verma
authors.forename: Pratichi
authors.initials: P
authors.lastname: Kothari
authors.forename: Morton
authors.initials: M
authors.lastname: Coleman
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D006801:Humans; D007457:Iodine Radioisotopes; D016403:Lymphoma, Large B-Cell, Diffuse / Q000000981:diagnostic imaging* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography / Q000379:methods; D011237:Predictive Value of Tests; D011241:Prednisone / Q000008:administration & dosage; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone